Financial News

Recent Quotes
My Watchlist
Indicators
Motherlode Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. (NY: SNY )

43.41 USD UNCHANGED
Last Price Updated: 5:16 PM EST, Dec 31, 2018 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Sanofi-Aventis S.A.

< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
Biond to receive $125 million upfront with more than $1 billion in potential development, regulatory, and sales milestones plus royalty payments 
From PR Newswire
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines
Moderna Provides Business Update and Announces Three New Development Programs in Infectious Disease Vaccines 
From Business Wire News Releases
Corinne Le Goff, Pharm.D. Will Join Moderna as Chief Commercial Officer on January 19
Corinne Le Goff, Pharm.D. will join Moderna as Chief Commercial Officer on January 19. 
From Business Wire News Releases
Canadians living with multiple sclerosis find support during COVID-19 pandemic through dedicated social media network
From PR Newswire
Anti-Fibrinolytic Drugs Market Size, Share, Price, Trends, Growth, Analysis, Key Players, Outlook, Report, Forecast 2021-2026 | ExpertMarketResearch.com
Tags iCN Internal Distribution English Extended Distribution
From iCrowdNewswire
Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease
* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD) 
From PR Newswire
EmergingGrowth.com Reports on Why Galectin Therapeutics is Due for a COVID-19 Makeover
Tags iCN Internal Distribution Google News English
From iCrowdNewswire
EmergingGrowth.com Reports on Why Galectin Therapeutics (GALT) is Due for a COVID-19 Makeover
Tags business/economy c:canada banking/finance/investment
From EIN Presswire
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their... 
From PR Newswire
Sanofi Genzyme continues research to improve the lives of patients with multiple sclerosis, with new data presented at MSVirtual2020
- New data on investigational brain-penetrant BTK inhibitor tolebrutinib (SAR442168) further support its potential in modulating disabling inflammatory processes within the central nervous system 
From PR Newswire
Biopharma Leaders Unite to Stand With Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
From GlobeNewswire News Releases
Biopharma Leaders Unite To Stand With Science
Biopharma leaders unite to stand with science. 
From Business Wire News Releases
Biopharma Leaders Unite to Stand with Science
The CEOs of AstraZeneca (LSE/STO/NYSE: AZN), BioNTech (NASDAQ: BNTX), GlaxoSmithKline plc (LSE/NYSE: GSK), Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK), known as MSD outside the United States and... 
From Business Wire News Releases
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Are Shareholders Getting a Fair Price?
From GlobeNewswire News Releases
PRINCIPIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRNB and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Principia Biopharma Inc. (NASDAQ: PRNB) breached their... 
From Business Wire News Releases
PRINCIPIA BIOPHARMA INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
From GlobeNewswire News Releases
(PRNB) Alert: Johnson Fistel Investigates Proposed Sale of Principia Biopharma; Is $100 a Fair Price?
Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Principia Biopharma Inc. ("Principia " or the "Company") (NASDAQ: PRNB) breached their... 
From PR Newswire
Sanofi to acquire Principia Biopharma
* Further strengthens core R&D areas of autoimmune and allergic diseases 
From PR Newswire
Sanofi H1 2020 business EPS(1) growth of 9.2%(2) driven by transformation
Sanofi (NASDAQ: SNY; EURONEXT: SAN) 
From PR Newswire
AllPennyStocks.com News: Plant-Based Biopharma Company Jumps to Six-Month High on Clinical Trials for Depression, ADHD
From SBWire - Latest Press Releases
Sanofi and MD Anderson announce strategic collaboration to accelerate oncology research and development
* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines 
From PR Newswire
Kymera Therapeutics And Sanofi Enter Into Strategic Partnership To Advance Novel Protein Degrader Therapies To Patients
- Kymera to receive $150 million upfront with more than $2 billion in potential milestones plus royalty payments - 
From PR Newswire
FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent 
From PR Newswire
Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II
- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate 
From PR Newswire
Sanofi and Sobi donate up to 500 million additional IUs of clotting factor to WFH Humanitarian Aid Program
* Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use 
From PR Newswire
Regeneron Announces Secondary Offering of its Common Stock Held by Sanofi and $5 Billion Stock Repurchase
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the commencement of an underwritten public secondary offering of its common stock through which Sanofi (NASDAQ: SNY) intends to exit its... 
From PR Newswire
Sanofi to showcase oncology portfolio and innovative pipeline at ASCO20 Virtual Scientific Program
- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class... 
From PR Newswire
NASDAQ:SNY Shareholder Notice: Investigation over Possible Violations of Securities Laws by Sanofi
San Diego, CA -- (SBWIRE) -- 05/06/2020 -- Sanofi is under investigation over potential securities laws violations by Sanofi in connection with certain financial statements. 
From SBWire - Latest Press Releases
Sanofi at forefront of fight against COVID-19 in Q1 2020
Sanofi (NASDAQ: SNY; EURONEXT: SAN) 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
58 59 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback